CD45RA, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG

Search, find, compare suppliers for anti-CD45RA, Human antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityCD45RA, Human
CloneREAL164
Host SpeciesRecombinant Human
Reactive Specieshuman
Isotypen/a
Formatphycoerythrin (PE) conjugate
Size100 tests in 200 µL
Concentration1:50
ApplicationsFlow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionCD45RA Antibody, anti-human, PE, REAlease®. Clone REAL164 is an antibody fragment derived from the full CD45RA antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL164 recognizes the human CD45RA antigen which is expressed on naive CD4+ and CD8+ T cells as well as on CD8+ effector T cells. CD45RA is also present on subsets of B and NK cells and on plasmacytoid dendritic cells. The CD45RA antibody recognizes the 220 kDa isoform of the leukocyte common antigen (LCA), a transmembrane tyrosine phosphatase. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
Immunogenn/a
Other NamesPtprc, B220, CD45, CD45R, GP180, L-CA, LY5, T200
Gene, Accession #n/a
Catalog #130-119-920
Price$370
Order / More InfoCD45RA, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Product Specific ReferencesCantisan, S. et al. (2010) CD45RA expression on HCMV-specific effector memory CD8+ T cells is associated with the duration and intensity of HCMV replication after transplantation. Clin. Immunol. 137 (1): 81-88. | Baba, N. et al. (2010) Interplay between CD45RA+ regulatory T cells and TNF-α in the regulation of human T?17 differentiation. Int. Immunol. 22: 237-244. | Braun, T. et al. (2012) Effector CD4+CD45RA-CD25brightFoxp3bright regulatory T cell (eTreg) distribution is significantly impaired in chronic myelomonocytic leukemia (CMML) and correlates with TET 2 mutational status. Blood 120: 2808-2808.
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197

macs@miltenyibiotec.de

https://www.miltenyibiotec.com

Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.